@incollection{,
	
					
					
					BE33685387C84302D4E4791E661E61D0
				,
	author={{Morgan,LR} and {Weiner,RS} and {Ware,ML} and {Bhandari,M} and {Mahmood,T} and {Friedlander,P}},
	journal={{Global Journal of Medical Research}},
	journal={{GJMR}}2249-46180975-588810.34257/GJMR,
	address={Cambridge, United States},
	publisher={Global Journals Organisation}2113133
}

@incollection{b0,
	
	
		,
	title={{}}
	
	
		,
	journal={{Cancer Facts and Figures}}
		
			,
	year={2020. 2020}
			,
	publisher={American Cancer Society}
		
	

}

@incollection{b1,
	
	
		,
	title={{Integrating AYA oncology care into the worlds of pediatric and adult oncology care to improve cancer outcomes}}
		,
	author={{
			HHayes-Lattin
		}}
	
	
		,
	journal={{The ASCO Post}}
		
			
			,
	year={December. 2016}
		
	

}

@book{b2,
	
	
		,
	title={{Brain tumors affect adolescents and young adults differently. HemOnc Today}}
		,
	author={{
			EWilson
		}}
		
			,
	year={June, 8-9, 2016}
		
	

}

@incollection{b3,
	
	
		,
	title={{A Growing identity for adolescent and young adult oncology}}
		,
	author={{
			ArkFranklin
		}}
	
	
		,
	journal={{Oncology Times}}
		
			38
		
	

}

@book{b4,
	
	
		,
	title={{Discussions on adolescent and young adult survivorship}}
		,
	author={{
			ESToronezos
		}}
		
			,
	year={2017 Cancer Survivor-ship Symposium, 2017. , 8-10, 2016}
		
	

}

@incollection{b5,
	
	
		,
	title={{The Tolerance and Safety of 4-Demethyl-4-cholesteryloxypenclomedine [DM-CHOC-PEN] in Adolescent and Young Adult (AYA) Subjects with Advanced Malignancies}}
		,
	author={{
			RSWeiner
		} and {
			Ware
		} and {
			Ml
		} and {
			TBhandari
		} and {
			Friedlander
		} and {
			LRMorgan
		}}
		
		
		
		
		
	
	
		,
	journal={{J. Transl. Sci}}
		
			3
			
			,
	year={2017}
		
	

}

@incollection{b6,
	
	
		,
	title={{Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer Agents}}
		,
	author={{
			LRMorgan
		} and {
			Struck
		} and {
			Rf
		} and {
			Waud
		} and {
			Wr
		} and {
			Jursic
		} and {
			Bs
		} and {
			DSerota
		} and {
			CPapagiannis
		} and {
			AHRodgers
		}}
		
		
		
		
		
		
		
		
		
	
	
		,
	journal={{Cancer Chemotherapy Pharmacology}}
		
			64
			
			,
	year={2009}
		
	

}

@incollection{b7,
	
	
		,
	title={{}}
		,
	author={{
			RSWeiner
		} and {
			PFriedlander
		} and {
			CGordon
		} and {
			YSaenger
		} and {
			Ware
		} and {
			Rl
		} and {
			TMahmood
		} and {
			AHRodgers
		} and {
			GBastian
		} and {
			SUrien
		} and {
			MBhandari
		} and {
			Morgan
		} and {
			Lr
		} and {
			J-JZhu
		}}
		
		
		
		
		
		
		
		
		
		
		
		
		
		demethyl-4- cholesteryoxycarbonylpenclomedine (DM-CHOC-
	
	
		,
	journal={{Results of Phase II cancer clinical trials for}}
		
			4
		
	

}

@incollection{b8,
	
	
	
	
		,
	booktitle={{Proc. Am. Assoc}}
				Am. Assoc
		
			,
	year={2016}
			58
			236
		
	

}

@incollection{b9,
	
	
		,
	title={{Early Phase I Results of 4-Demethyl-4-cholesteryloxypenclomedine [DM-CHOC-PEN] in Adolescent and Young Adult (AYA) Subjects with Advanced Malignancies}}
		,
	author={{
			LRMorgan
		} and {
			Weiner
		} and {
			Rs
		} and {
			Ware
		} and {
			Ml
		} and {
			MBhandari
		} and {
			PMahmood
		} and {
			T
		} and {
			Rodgers
		} and {
			Friedlander
		}}
		
		
		
		
		
		
		
		
		
	
	
		,
	journal={{J Cancer Res Updates}}
		
			7
			
			,
	year={2018}
		
	

}

@incollection{b10,
	
	
		,
	title={{Weiner et al, The Tolerance and Safety of 4-Demethyl-4-cholesteryloxypenclomedine}}
		,
	author={{
			LRMorgan
		}}
		DM-CHOC-PEN
	
	
		,
	booktitle={{Adolescent and Young Adult (AYA) Subjects with Advanced Malignancies" (see Ref. 6)}}
				
			,
	year={2017}
			2
			
		
	
	,
	note={Commentary on}

}

@book{b11,
	
	
		,
	title={{What do we still need to know about adolescent and young adult survivorship? Oncology Practice Management}}
		,
	author={{
			CDoyle
		}}
		
			,
	year={May, 34-35, 2017}
		
	

}

@book{b12,
	
	
		,
	title={{}}
		,
	author={{
			Dekk-TecBlog
		}}
		
	
	,
	note={dti-aya -internet}

}